MA51978A - Phénytoïne à usage topique destinée a être utilisée dans le traitement de la douleur neuropathique périphérique - Google Patents
Phénytoïne à usage topique destinée a être utilisée dans le traitement de la douleur neuropathique périphériqueInfo
- Publication number
- MA51978A MA51978A MA051978A MA51978A MA51978A MA 51978 A MA51978 A MA 51978A MA 051978 A MA051978 A MA 051978A MA 51978 A MA51978 A MA 51978A MA 51978 A MA51978 A MA 51978A
- Authority
- MA
- Morocco
- Prior art keywords
- phenytoin
- treatment
- neuropathic pain
- peripheral neuropathic
- topical
- Prior art date
Links
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 title 1
- 208000004296 neuralgia Diseases 0.000 title 1
- 208000021722 neuropathic pain Diseases 0.000 title 1
- 230000002093 peripheral effect Effects 0.000 title 1
- 229960002036 phenytoin Drugs 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2017931 | 2016-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51978A true MA51978A (fr) | 2021-01-20 |
Family
ID=57796933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051978A MA51978A (fr) | 2016-12-06 | 2017-12-06 | Phénytoïne à usage topique destinée a être utilisée dans le traitement de la douleur neuropathique périphérique |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11285099B2 (fr) |
| EP (1) | EP3551166B1 (fr) |
| JP (1) | JP7264813B2 (fr) |
| CN (1) | CN110248644A (fr) |
| AU (1) | AU2017371467B2 (fr) |
| BR (1) | BR112019011743A2 (fr) |
| CA (1) | CA3046055A1 (fr) |
| CL (1) | CL2019001550A1 (fr) |
| DK (1) | DK3551166T3 (fr) |
| DO (1) | DOP2019000156A (fr) |
| EA (1) | EA201991341A1 (fr) |
| ES (1) | ES2991885T3 (fr) |
| FI (1) | FI3551166T3 (fr) |
| IL (1) | IL267114B2 (fr) |
| MA (1) | MA51978A (fr) |
| MX (1) | MX2019006640A (fr) |
| PH (1) | PH12019550093A1 (fr) |
| PT (1) | PT3551166T (fr) |
| UA (1) | UA125040C2 (fr) |
| WO (1) | WO2018106107A1 (fr) |
| ZA (1) | ZA201906473B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12005034B2 (en) | 2017-04-25 | 2024-06-11 | Algotherapeutix | Topical pharmaceutical composition comprising at least amitriptyline, for the treatment of peripheral neuropathic pain |
| FR3095589B1 (fr) * | 2019-05-02 | 2021-05-07 | Air Liquide | Mélange gazeux inhalable pour traiter les douleurs chroniques chez des patients recevant des médicaments de plusieurs classes thérapeutiques |
| PL4025183T3 (pl) | 2019-09-02 | 2025-09-22 | Syddansk Universitet | Induktory P-gp do stosowania w ochronie przed skutkami ubocznymi chemioterapii takimi jak neuropatia obwodowa wywołana chemioterapią (CIPN) oraz utrata włosów |
| FR3108841B1 (fr) | 2020-04-06 | 2023-11-03 | Algotherapeutix | Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline |
| CN114681340A (zh) * | 2022-04-13 | 2022-07-01 | 肌赋萃生物科技(上海)有限公司 | 一种含有脂质包裹稳定技术的脂质屏障修复护肤品及其制备方法 |
| WO2024120461A1 (fr) * | 2022-12-09 | 2024-06-13 | 荣昌生物制药(烟台)股份有限公司 | Utilisation d'inducteurs de cyp3a4/5 dans le traitement ou le soulagement d'une neuropathie périphérique |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571521A (en) | 1984-01-16 | 1996-11-05 | Lasker; Sigmund E. | Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition |
| JPH0772190B2 (ja) * | 1985-02-26 | 1995-08-02 | エーザイ株式会社 | ヒダントイン誘導体 |
| JP3031973B2 (ja) | 1990-08-16 | 2000-04-10 | 富士レビオ株式会社 | フェニトイン誘導体 |
| US6113921A (en) * | 1993-03-23 | 2000-09-05 | Pharmos Corp. | Topical and transdermal delivery system utilizing submicron oil spheres |
| CN1046199C (zh) * | 1994-12-13 | 1999-11-10 | 凌吉安 | 复方消炎止痛霜剂 |
| DE69733081T2 (de) | 1996-08-23 | 2006-05-11 | Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) | Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen |
| WO2001000191A2 (fr) * | 1999-06-23 | 2001-01-04 | Warner-Lambert Company | Utilisation de fosphenytoine pour le traitement de douleur neuropathique aigue |
| US20040191276A1 (en) | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| HUP0304078A2 (hu) * | 2001-05-15 | 2004-04-28 | Warner-Lambert Co. Llc | Tömörítési eljárás nátrium-fenitoin gyógyszerkészítmény előállítására |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| CA2574555A1 (fr) | 2004-08-03 | 2006-02-09 | Royal College Of Surgeons In Ireland | Formulations de phenytoine, et utilisations associees pour guerir des blessures |
| US20060034910A1 (en) * | 2004-08-09 | 2006-02-16 | Sanjay Patel | Pharmaceutical composition for extended release of phenytoin sodium |
| CN101069692B (zh) * | 2006-05-08 | 2011-04-20 | 范敏华 | 含积雪草总甙的药物制剂及其制备方法 |
| WO2008079727A2 (fr) | 2006-12-22 | 2008-07-03 | Allergan, Inc. | Compositions contenant un agoniste du récepteur adrénergique pan-alpha-2 et un anticonvulsif, destinées à traiter la douleur chronique |
| US20110275137A1 (en) * | 2008-04-14 | 2011-11-10 | Seikagaku Corporation | Improving agent for neuropathic pain |
| CA2729346A1 (fr) | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Traitement neuro-affectif regional topique |
| AU2009296457A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| KR101271219B1 (ko) * | 2011-01-27 | 2013-06-07 | 광주과학기술원 | 신규한 하이단토인 유도체 및 이의 용도 |
| WO2012176668A1 (fr) | 2011-06-20 | 2012-12-27 | 久光製薬株式会社 | Cataplasme contenant de la lidocaïne |
| US20130184351A1 (en) | 2011-12-21 | 2013-07-18 | Jar Laboratories | Lidocaine patch and methods of use thereof |
| US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
| US20160303203A1 (en) * | 2013-12-09 | 2016-10-20 | Keshav Malshe | Compositions and methods for the treatment of wounds |
| CN106075556A (zh) | 2016-06-02 | 2016-11-09 | 四川奎星医用高分子制品有限责任公司 | 含有促进伤口愈合药物的医用复合壳聚糖凝胶 |
-
2017
- 2017-12-06 FI FIEP17817927.1T patent/FI3551166T3/fi active
- 2017-12-06 PT PT178179271T patent/PT3551166T/pt unknown
- 2017-12-06 EP EP17817927.1A patent/EP3551166B1/fr active Active
- 2017-12-06 MX MX2019006640A patent/MX2019006640A/es unknown
- 2017-12-06 DK DK17817927.1T patent/DK3551166T3/da active
- 2017-12-06 AU AU2017371467A patent/AU2017371467B2/en active Active
- 2017-12-06 CN CN201780082443.1A patent/CN110248644A/zh active Pending
- 2017-12-06 IL IL267114A patent/IL267114B2/en unknown
- 2017-12-06 EA EA201991341A patent/EA201991341A1/ru unknown
- 2017-12-06 BR BR112019011743A patent/BR112019011743A2/pt not_active Application Discontinuation
- 2017-12-06 US US16/467,179 patent/US11285099B2/en active Active
- 2017-12-06 UA UAA201907615A patent/UA125040C2/uk unknown
- 2017-12-06 CA CA3046055A patent/CA3046055A1/fr active Pending
- 2017-12-06 JP JP2019531112A patent/JP7264813B2/ja active Active
- 2017-12-06 WO PCT/NL2017/050814 patent/WO2018106107A1/fr not_active Ceased
- 2017-12-06 ES ES17817927T patent/ES2991885T3/es active Active
- 2017-12-06 MA MA051978A patent/MA51978A/fr unknown
-
2019
- 2019-06-06 CL CL2019001550A patent/CL2019001550A1/es unknown
- 2019-06-06 DO DO2019000156A patent/DOP2019000156A/es unknown
- 2019-06-06 PH PH12019550093A patent/PH12019550093A1/en unknown
- 2019-10-01 ZA ZA2019/06473A patent/ZA201906473B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110248644A (zh) | 2019-09-17 |
| PT3551166T (pt) | 2024-10-28 |
| CA3046055A1 (fr) | 2018-06-14 |
| IL267114B2 (en) | 2024-08-01 |
| AU2017371467B2 (en) | 2023-06-01 |
| CL2019001550A1 (es) | 2020-02-28 |
| ZA201906473B (en) | 2020-07-29 |
| IL267114A (en) | 2019-08-29 |
| AU2017371467A1 (en) | 2019-07-25 |
| US20200276106A1 (en) | 2020-09-03 |
| DK3551166T3 (da) | 2024-10-21 |
| IL267114B1 (en) | 2024-04-01 |
| US11285099B2 (en) | 2022-03-29 |
| FI3551166T3 (fi) | 2024-10-04 |
| JP2020500915A (ja) | 2020-01-16 |
| EA201991341A1 (ru) | 2019-12-30 |
| UA125040C2 (uk) | 2021-12-29 |
| BR112019011743A2 (pt) | 2019-10-22 |
| MX2019006640A (es) | 2019-08-01 |
| DOP2019000156A (es) | 2020-07-15 |
| WO2018106107A1 (fr) | 2018-06-14 |
| JP7264813B2 (ja) | 2023-04-25 |
| EP3551166B1 (fr) | 2024-08-21 |
| ES2991885T3 (es) | 2024-12-05 |
| EP3551166A1 (fr) | 2019-10-16 |
| PH12019550093A1 (en) | 2020-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3706755A4 (fr) | Ganaxolone destinée à être utilisée dans le traitement de troubles épileptiques génétiques | |
| MA45192A (fr) | Traitement d'association | |
| MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
| MA46608A (fr) | Formulation liposomale destinée à être utilisée dans le traitement du cancer | |
| EP3646352A4 (fr) | Composition polymère destinée à être utilisée dans des câbles | |
| MA50800A (fr) | Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson | |
| EP3735970C0 (fr) | Cébranopadol pour le traitement de la douleur chez des sujets à fonction hépatique altérée et/ou fonction rénale altérée | |
| DK3551166T3 (da) | Topisk phenytoin til anvendelse i behandling af periferisk neuropatisk smerte | |
| EP3419981A4 (fr) | Polythérapies utilisées dans le traitement de l'amyotrophie spinale | |
| ME03351B (fr) | Composé stéroïde destiné à être utilisé dans le traitement de l'encéphalopathie hépatique | |
| EP3848022C0 (fr) | Agent thérapeutique pour utilisation dans le traitement d'infections | |
| EP3636598A4 (fr) | Appareil de traitement de liquide | |
| EP3267987A4 (fr) | Curcumines chimiquement modifiées destinées à être utilisées dans la production de lipoxines | |
| MA43861A (fr) | Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| HUE063930T2 (hu) | Bõrre felhelyezhetõ orvostechnikai eszköz | |
| EP3806679A4 (fr) | Capsules destinées à être utilisées dans des vaporisateurs personnels | |
| EP4009982A4 (fr) | Ganaxolone destinée à être utilisée dans le traitement de l'état de mal épileptique | |
| EP3458062A4 (fr) | Traitement de la douleur | |
| EP3397063A4 (fr) | Utilisation de microbulles et de nanobulles dans le traitement de liquide | |
| MA51128A (fr) | Inhibiteurs c5ar destinés à être utilisés dans le traitement de la douleur iatrogène induite par la chimiothérapie | |
| EP2968328A4 (fr) | Compositions destinées à être utilisées en traitement de troubles oculaires à l'aide de dipyridamole | |
| EP3500300A4 (fr) | Composition immunosuppressante destinée à être utilisée dans le traitement de troubles immunologiques | |
| EP4048245A4 (fr) | Compositions de cannabidiol destinées à être utilisées dans le traitement de pathologies cardiaques | |
| MA44660A (fr) | (+)-azasetron destiné à être utilisé dans le traitement de troubles de l'oreille |